TY  - JOUR
AU  - de la Cruz-Merino, Luis
AU  - Di Guardo, Lorenza
AU  - Grob, Jean-Jacques
AU  - Venosa, Alfredo
AU  - Larkin, James
AU  - McArthur, Grant A
AU  - Ribas, Antoni
AU  - Ascierto, Paolo A
AU  - Evans, Jeffrey T R
AU  - Gomez-Escobar, Antonio
AU  - Barteselli, Giulio
AU  - Eng, Susan
AU  - Hsu, Jessie J
AU  - Uyei, Anne
AU  - Dréno, Brigitte
PY  - 2017
DO  - 10.1186/s12967-017-1246-0
UR  - http://hdl.handle.net/10668/11340
T2  - Journal of translational medicine
AB  - Serous chorioretinopathy has been associated with MEK inhibitors, including cobimetinib. We describe the clinical features of serous retinopathy observed with cobimetinib in patients with BRAF V600-mutated melanoma treated in the Phase III coBRIM...
LA  - en
KW  - Cobimetinib
KW  - MEK inhibition
KW  - Melanoma
KW  - Serous retinopathy
KW  - Visual disturbance
KW  - Adult
KW  - Aged
KW  - Azetidines
KW  - Central Serous Chorioretinopathy
KW  - Female
KW  - Humans
KW  - Indoles
KW  - Male
KW  - Melanoma
KW  - Middle Aged
KW  - Mutation
KW  - Piperidines
KW  - Proto-Oncogene Proteins B-raf
KW  - Recurrence
KW  - Skin Neoplasms
KW  - Sulfonamides
KW  - Time Factors
KW  - Vemurafenib
TI  - Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study.
TY  - research article
VL  - 15
ER  -